Nicox: 2023 Ordinary Shareholder Meeting to be held on June 1st, 2023
April 24 2023 - 1:30AM
Nicox: 2023 Ordinary Shareholder Meeting to be held on June 1st,
2023
Press Release |
Nicox: 2023 Ordinary Shareholder Meeting to be held on June 1st,
2023 |
April
24, 2023 – release at 7:30 am CET Sophia Antipolis,
FranceNicox SA (Euronext Paris: FR0013018124,
COX), an international ophthalmology company, convenes an ordinary
shareholder meeting on Thursday
June 1, 2023
at 2:00 pm CEST in the offices of BuroClub -
Drakkar 2 - Bâtiment D - 2405 route des Dolines - 06560 Valbonne
Sophia Antipolis - France.The documents mentioned in articles
R.22.10-23 of the French Code de commerce, including a proxy voting
form, will be sent to the shareholders upon written request. These
documents will also be made available to shareholders at the
headquarters of the Company and on its website (www.nicox.com) by
May 11, 2023.Shareholders may vote by proxy, by internet or by
attending the shareholder meeting in person. A guide explaining how
to vote, and notably how to vote by internet, is available on the
Company’s website. Shareholders may also contact the Company’s
Investor Relations team at ag2023nicox@nicox.com for any question
on the voting process.In the event the quorum is not reached on
first call, Nicox will convene an ordinary shareholder meeting on a
second call on Thursday June 15, 2023 at 2:00 pm CEST in the
offices of BuroClub - Drakkar 2 - Bâtiment D - 2405 route des
Dolines - 06560 Valbonne Sophia Antipolis – France |
About Nicox |
Nicox SA is an international ophthalmology company developing
innovative solutions to help maintain vision and improve ocular
health. Nicox’s lead program in clinical development is NCX 470, a
novel nitric oxide-donating bimatoprost, for lowering intraocular
pressure in patients with open-angle glaucoma or ocular
hypertension. The company is also conducting research on NCX 1728,
a nitric oxide-donating phosphodiesterase 5 inhibitor, in retinal
conditions. NCX 4251, a novel, patented, ophthalmic suspension of
fluticasone propionate nanocrystals for topical ocular application
for dry eye disease, is being developed by Ocumension Therapeutics
in China under an exclusive license agreement and is available for
partnering elsewhere. Nicox generates revenue from VYZULTA® in
glaucoma, licensed exclusively worldwide to Bausch + Lomb, and
ZERVIATE® in allergic conjunctivitis, licensed in multiple
geographies, including to Eyevance Pharmaceuticals, LLC (a wholly
owned subsidiary of Santen Pharmaceutical Co., Ltd.), in the U.S.
and Ocumension Therapeutics in the Chinese and in the majority of
Southeast Asian markets. Nicox is headquartered
in Sophia Antipolis, France, is listed on Euronext Paris
(Compartment C: Mid Caps; Ticker symbol: COX) and is part of the
CAC Healthcare index.For more information on Nicox, its products or
pipeline, please visit: www.nicox.com. |
Analyst coverage |
Bryan, Garnier & Co
Eric
Yoo Paris,
FranceEdison Investment
Research Pooya
Hemami London,
UKH.C. Wainwright &
Co Yi
Chen New York,
U.S.Kepler
Cheuvreux Arsene
Guekam Paris,
France |
|
The views expressed by analysts in their coverage of Nicox are
those of the author and do not reflect the views of Nicox.
Additionally, the information contained in their reports may not be
correct or current. Nicox disavows any obligation to correct or to
update the information contained in analyst reports. |
Contacts |
|
NicoxGavin SpencerExecutive Vice President, Chief
Business Officer& Head of Corporate Development T +33 (0)4 97
24 53 00communications@nicox.com |
|
Forward-Looking Statements |
The information contained in this document may be modified without
prior notice. This information includes forward-looking statements.
Such forward-looking statements are not guarantees of future
performance. These statements are based on current expectations or
beliefs of the management of Nicox S.A. and are subject to a number
of factors and uncertainties that could cause actual results to
differ materially from those described in the forward-looking
statements. Nicox S.A. and its affiliates, directors, officers,
employees, advisers or agents, do not undertake, nor do they have
any obligation, to provide updates or to revise any forward-looking
statements.Risks factors which are likely to have a material effect
on Nicox’s business are presented in the 3rd chapter of the
‘Document d’enregistrement universel, rapport financier annuel et
rapport de gestion 2021’ filed with the French Autorité des Marchés
Financiers (AMF) on April 29, 2022 whose first amendment has been
filed with the AMF on May 19, 2022, in the 2nd chapter of the
second amendment filed with the AMF on November 22, 2022 and in the
2nd chapter of the Securities noted filed with the AMF on November
22, 2022 which are available on Nicox’s website
(www.nicox.com) |
Nicox S.A.Drakkar 2Bât D, 2405 route des
Dolines06560 Valbonne, FranceT +33 (0)4 97 24 53 00F +33 (0)4 97 24
53 99 |
|
- EN_AGO June PR avis de réunion_F_20230424
Nicox (LSE:0RCQ)
Historical Stock Chart
From Apr 2024 to May 2024
Nicox (LSE:0RCQ)
Historical Stock Chart
From May 2023 to May 2024